|

NUTRIMOOD-Inflammation and Depressive Comorbidity in Obesity: Modulation by Omega-3 Polyunsaturated Fatty Acids Status

RECRUITINGN/ASponsored by National Science and Technology Council, Taiwan
Actively Recruiting
PhaseN/A
SponsorNational Science and Technology Council, Taiwan
Started2025-03-01
Est. completion2027-03
Eligibility
Age18 Years – 54 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07439744

Summary

A 12-week, randomized, placebo-controlled trial testing the efficacy of n-3 PUFA treatment (EPA, 2 g/day) in alleviating depressive symptoms in a subgroup of obese subjects with comorbid depression and low n-3 PUFA status (n-3 index \< 8%) (81), from the Taiwanese cohort. Associations with PLA2/COX2 genotypes, lifestyle, nutritional profiles and gut microbiota will also be determined.

Eligibility

Age: 18 Years – 54 YearsHealthy volunteers accepted
Inclusion Criteria:

* Major depressive disorder.
* Antidepressant drug-free.

Exclusion Criteria:

* Schizophrenia
* Mania
* Anxiety disorders (except for social phobia and generalized anxiety that are often comorbid with MDD)
* Obsessive-compulsive disorder
* Post-traumatic stress disorder
* Alcohol or drug abuse/dependence (except for nicotine)
* Active suicidal ideation
* Serious medical/neurological conditions, especially requiring corticosteroid/non-steroidal anti-inflammatory or immunosuppressive therapies or chronic thyroid hormone replacement

Conditions3

DepressionMDDObese Adults

Browse More Trials

Depression trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.